Evidence map›Paper›PMID 25541979›Full record

ArticlePloS one2014

Prenatal metformin exposure in a maternal high fat diet mouse model alters the transcriptome and modifies the metabolic responses of the offspring.

Henriikka Salomäki, Merja Heinäniemi, Laura H Vähätalo, Liisa Ailanen, Kim Eerola, Suvi T Ruohonen, Ullamari Pesonen, Markku Koulu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed, 2 pooled it
6.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 2 syntheses or guidelines pooled it, 60 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Early life impacts of maternal obesity: a window of opportunity to improve the health of two generations.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2023
    Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Frontiers in endocrinology · 2021
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Henriikka SalomäkiDepartment of Pharmacology, Drug Development and Therapeutics, Institute of Biomedicine, University of Turku, FI-20014 Turku, Finland; Drug Research Doctoral Programme (DRDP), University of Turku, Turku, Finland.
Merja HeinäniemiSchool of Medicine, Institute of Biomedicine, University of Eastern Finland, FI-70211 Kuopio, Finland.
Laura H VähätaloDepartment of Pharmacology, Drug Development and Therapeutics, Institute of Biomedicine, University of Turku, FI-20014 Turku, Finland; Drug Research Doctoral Programme (DRDP), University of Turku, Turku, Finland; Turku Center for Disease Modeling (TCDM), University of Turku, FI-20014 Turku, Finland.
Liisa AilanenDepartment of Pharmacology, Drug Development and Therapeutics, Institute of Biomedicine, University of Turku, FI-20014 Turku, Finland; Drug Research Doctoral Programme (DRDP), University of Turku, Turku, Finland; Turku Center for Disease Modeling (TCDM), University of Turku, FI-20014 Turku, Finland.
Kim EerolaDepartment of Pharmacology, Drug Development and Therapeutics, Institute of Biomedicine, University of Turku, FI-20014 Turku, Finland; Drug Research Doctoral Programme (DRDP), University of Turku, Turku, Finland; Turku Center for Disease Modeling (TCDM), University of Turku, FI-20014 Turku, Finland.
Suvi T RuohonenDepartment of Pharmacology, Drug Development and Therapeutics, Institute of Biomedicine, University of Turku, FI-20014 Turku, Finland; Turku Center for Disease Modeling (TCDM), University of Turku, FI-20014 Turku, Finland.
Ullamari PesonenDepartment of Pharmacology, Drug Development and Therapeutics, Institute of Biomedicine, University of Turku, FI-20014 Turku, Finland.
Markku KouluDepartment of Pharmacology, Drug Development and Therapeutics, Institute of Biomedicine, University of Turku, FI-20014 Turku, Finland.
University of Turku · FIUniversity of Eastern Finland · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsDespite the wide use of metformin in metabolically challenged pregnancies, the long-term effects on the metabolism of the offspring are not known. We studied the long-term effects of prenatal metformin exposure during metabolically challenged pregnancy in mice. MATERIALS AND

methodsFemale mice were on a high fat diet (HFD) prior to and during the gestation. Metformin was administered during gestation from E0.5 to E17.5. Male and female offspring were weaned to a regular diet (RD) and subjected to HFD at adulthood (10-11 weeks). Body weight and several metabolic parameters (e.g. body composition and glucose tolerance) were measured during the study. Microarray and subsequent pathway analyses on the liver and subcutaneous adipose tissue of the male offspring were performed at postnatal day 4 in a separate experiment.

resultsPrenatal metformin exposure changed the offspring's response to HFD. Metformin exposed offspring gained less body weight and adipose tissue during the HFD phase. Additionally, prenatal metformin exposure prevented HFD-induced impairment in glucose tolerance. Microarray and annotation analyses revealed metformin-induced changes in several metabolic pathways from which electron transport chain (ETC) was prominently affected both in the neonatal liver and adipose tissue.

conclusionThis study shows the beneficial effects of prenatal metformin exposure on the offspring's glucose tolerance and fat mass accumulation during HFD. The transcriptome data obtained at neonatal age indicates major effects on the genes involved in mitochondrial ATP production and adipocyte differentiation suggesting the mechanistic routes to improved metabolic phenotype at adulthood.

Indexed as

AdipocytesAdipokinesAdipose Tissue, WhiteAnimalsBlood GlucoseBody WeightCell SizeDiet, High-FatFemaleFetusGlucose Tolerance TestLipidsLiverMaleMetforminMiceAdipokinesBlood GlucoseLipidsMetformin

Identifiers

PMID25541979
PMCPMC4277397
OpenAlexW1997868883

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.